3 completed, 1 withdrawn. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Withdrawn 1 |
Follow AKCEA-ANGPTL3-LRx: new trials by email Literature Review of AKCEA-ANGPTL3-LRx trials Research Report on AKCEA-ANGPTL3-LRx
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL) AKCEA-ANGPTL3-LRx - Familial Partial Lipodystrophy | Phase 2 | Completed | Akcea Therapeutics | 4 | 2018-06-15 | 2021-02-16 |
| Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With Homozygous Familial Hypercholesterolemia (HoFH) AKCEA-ANGPTL3-LRX - Homozygous Familial Hypercholesterolemia | Phase 2 | Withdrawn | Akcea Therapeutics | 2018-04-12 | 2018-12-03 | |
| Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease Placebo, ISIS 703802 40 mg, ISIS 703802 80 mg - NAFLD, Diabetes Mellitus, Type 2 | Phase 2 | Completed | Akcea Therapeutics | 105 | 2017-12-21 | 2021-02-01 |
| Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS) AKCEA-ANGPTL3-LRx - Familial Chylomicronemia Syndrome, Lipoprotein Lipase Deficiency | Phase 2 | Completed | Akcea Therapeutics | 3 | 2017-12-21 | 2021-01-07 |
Dyslipidemias (2) · Lipid Metabolism Disorders (2) · Metabolic Diseases (2) · Diabetes Mellitus (1) · Diabetes Mellitus, Lipoatrophic (1) · Diabetes Mellitus, Type 2 (1) · Digestive System Diseases (1) · Endocrine System Diseases (1) · Familial hyperchylomicronemia syndrome (1) · Fatty Liver (1) · Genetic Diseases, Inborn (1) · Glucose Metabolism Disorders (1) · Homozygous Familial Hypercholesterolemia (1) · Hyperlipidemias (1) · Hyperlipoproteinemia Type I (1)
Canada (3) · United States (2)